Intellia Therapeutics to Present at November Healthcare Investor Conferences
November 08 2018 - 4:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, will participate
in the following upcoming healthcare conferences in November:
Tuesday, November 13, 2018Credit Suisse
Healthcare ConferenceLocation: Scottsdale, ArizonaTime:
2:50pm MT (4:50pm ET)
Thursday, November 15, 2018Jefferies
London Healthcare ConferenceLocation: London, United
KingdomTime: 12:40pm GMT (7:40am ET)
Thursday, November 29, 2018Barclays
Gene Editing and Gene Therapy SummitLocation: New York,
NYTime: 3:00pm ET
A live webcast of Intellia’s presentations at the Credit Suisse
Healthcare Conference and Jefferies London Healthcare Conference
will be accessible through the Events and Presentations page of the
Investor Relations section of the company’s website at
www.intelliatx.com. To access the webcasts, please log on to the
Intellia website approximately 15 minutes prior to the start time
to ensure adequate time for any software downloads that may be
required. A replay of the webcasts will be available on Intellia’s
website for approximately 14 days following each conference.
About Intellia TherapeuticsIntellia
Therapeutics is a leading genome editing company focused on
developing proprietary, curative therapeutics using the CRISPR/Cas9
system. Intellia believes the CRISPR/Cas9 technology has the
potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases, or can replace patients’ diseased
cells. The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow
us on Twitter @intelliatweets.
Investor
Contact:
Lindsey Trickett Vice President, Investor Relations +1 857-285-6211
lindsey.trickett@intelliatx.com
Media Contact:Jennifer Mound Smoter Senior Vice
President, External Affairs & Communications +1 857-706-1071
jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Apr 2024 to May 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From May 2023 to May 2024